Table 1B.
Demographics and clinical data of TGCG patients grouped by histological phenotypes.
| AR n=57 |
CR n=27 |
TX n=29 |
p | |
|---|---|---|---|---|
| Recipient age (years) | 44.7+13.9 | 45.1+15.7 | 52.9+14.2 | NS |
| Female recipients (%) | 33.3 | 44.4 | 24.4 | NS |
| Recipient race (W/NW) | 38.6/61.4 | 46.3/53.7 | 72.4/27.6 | 0.01 |
| Deceased donor (%) | 63.2 | 61.1 | 44.8 | 0.04 |
| HLA mismatch | 5.0+2.0 | 5.0+2.0 | 4.38+3.4 | NS |
| PRA ≥ 20 (%) | 13.1 | 19.4 | 25.0 | NS |
| Induction therapy‡ (%) | 35.1 | 37.1 | 44.8 | NS |
| Time to biopsy (median months; IQR) | 34.7+39.2 | 55.9+48.1 | 32.3+47.6 | 0.01 |
| IS at biopsy TAC/MMF/Pred (%) | 48.0 | 43.1 | 86.3 | NS |
| CSA/MMF/Pred (%) | 28.0 | 29.4 | 4.6 | NS |
| mTORi/MMF/Pred (%) | 20.0 | 15.7 | 4.6 | NS |
| Donor age (years) | 40.3+13.9 | 41.1+15.2 | 38.9+14.3 | NS |
| Female donor (%) | 43.9 | 59.3 | 24.4 | 0.005 |
| Creatinine | 3.4+2.8 | 3.1+2.2 | 2.1+1.9 | 0.03 |
Values are expressed as mean ± standard deviation unless otherwise indicated. NS, not significant; AR, Acute Rejection; CR (IFTA/Chronic rejection); TX, excellent functioning kidney; HLA, Human Leukocyte Antigen; PRA, Panel Reactive Antibody; W; white; NW (Non-White – other races).